• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hospira slides after taking $134M charge on infusion pump phase-out

Hospira slides after taking $134M charge on infusion pump phase-out

May 1, 2013 By Brad Perriello

Hospira

Hospira (NYSE:HSP) took a $134 million charge during the 1st quarter on its plan to "retire" some of its older, trouble-plagued infusion pumps and lowered its sales and earnings guidance.

Investors sent HOSP shares down some 2% today in response.

Lake Forest, Ill.-based Hospira said it will gradually phase out its Symbiq, GemStar and Plum infusion pumps over the next 2-3 years as it brings newer devices into the pipeline. The company has struggled since the FDA last year banned importation of some of its infusion pumps made in Costa Rica.

The decision pushed Hospira’s sales down 8.5% to $884.0 million during the 3 months ended March 31, plunging the company into red ink for the quarter. Losses reached $76.6 million, or 46¢ per share, compared with profits of $40.2 million, or 24¢ per share, during Q1 2013.

Adjusted to exclude the 1-time items, earnings per share topped Wall Street’s forecast by 8¢, at 52¢ per share. Still, HOSP shares were off 2.6% today as of about 1:10 p.m., trading at $32.25 each.

"Given the ever-expanding focus in healthcare on improving patient safety and clinical outcomes, we see our device business as a major strategic growth driver for Hospira and are committed to sustaining our leadership position through current and future investments," chief commercial officer Richard Davies said in prepared remarks. "Hospira is acutely aware of the importance of our devices globally to the patients we serve, and we will work closely with our customers to ensure a seamless transition throughout this process."

Hospira said it now expects to post sales declines of -2% to -4% or -1% to 1% excluding the impact of the phase-outs. Adjusted EPS are forecast to be $2-$2.10 for the year, down from prior guidance of $2.05 to $2.20.

Hospira recalled the Symbiq in November 2012 over a touchscreen issue. The FDA gave that recall its highest-risk Class I status over concerns that the software could prevent the pump from responding correctly to user selections. Later that month the federal watchdog agency blocked new imports of Symbiq systems into the U.S.

Just months before the Symbiq recall, the FDA had chided Hospira over violations at the Costa Rica facility, saying that the company mishandled a September 2011 recall of the Plum infusion pumps.

The FDA cited Hospira for a "failure to identify the actions needed to correct and prevent recurrence of nonconforming product and other quality problems" as well as a "failure to implement and record changes in methods and procedures needed to correct and prevent identified quality problems."

Filed Under: Drug Pumps, MassDevice Earnings Roundup, News Well, Recalls Tagged With: 2013, Hospira Inc., Q1

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy